clinical trial · NCT06245291
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
Hepatitis B, ChronicImdusiranDurvalumab
brief summary
This is a phase 2a, open-label, multicenter study investigating the safety, tolerability, and antiviral activity of durvalumab administered at targeted times during a 48-week treatment period of imdusiran in virologically-suppressed CHB subjects
started
May 1, 2024
primary completion
Aug 1, 2024
completion
Aug 1, 2024
last updated
Aug 12, 2024
official title
A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol